Insmed (INSM) Competitors $70.53 -0.06 (-0.08%) (As of 12/24/2024 04:20 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends INSM vs. TAK, ALNY, TEVA, BGNE, UTHR, RPRX, VTRS, GMAB, SMMT, and RDYShould you be buying Insmed stock or one of its competitors? The main competitors of Insmed include Takeda Pharmaceutical (TAK), Alnylam Pharmaceuticals (ALNY), Teva Pharmaceutical Industries (TEVA), BeiGene (BGNE), United Therapeutics (UTHR), Royalty Pharma (RPRX), Viatris (VTRS), Genmab A/S (GMAB), Summit Therapeutics (SMMT), and Dr. Reddy's Laboratories (RDY). These companies are all part of the "pharmaceutical preparations" industry. Insmed vs. Takeda Pharmaceutical Alnylam Pharmaceuticals Teva Pharmaceutical Industries BeiGene United Therapeutics Royalty Pharma Viatris Genmab A/S Summit Therapeutics Dr. Reddy's Laboratories Takeda Pharmaceutical (NYSE:TAK) and Insmed (NASDAQ:INSM) are both large-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their community ranking, valuation, institutional ownership, dividends, earnings, profitability, media sentiment, analyst recommendations and risk. Do insiders & institutionals believe in TAK or INSM? 9.2% of Takeda Pharmaceutical shares are held by institutional investors. 0.0% of Takeda Pharmaceutical shares are held by company insiders. Comparatively, 4.6% of Insmed shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has higher valuation and earnings, TAK or INSM? Takeda Pharmaceutical has higher revenue and earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTakeda Pharmaceutical$4.55T0.01$994.06M$0.5822.71Insmed$342.96M36.79-$749.57M-$5.55-12.71 Do analysts recommend TAK or INSM? Insmed has a consensus price target of $83.67, suggesting a potential upside of 18.63%. Given Insmed's stronger consensus rating and higher possible upside, analysts clearly believe Insmed is more favorable than Takeda Pharmaceutical.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Takeda Pharmaceutical 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Insmed 0 Sell rating(s) 0 Hold rating(s) 16 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is TAK or INSM more profitable? Takeda Pharmaceutical has a net margin of 6.49% compared to Insmed's net margin of -252.01%. Takeda Pharmaceutical's return on equity of 10.00% beat Insmed's return on equity.Company Net Margins Return on Equity Return on Assets Takeda Pharmaceutical6.49% 10.00% 4.78% Insmed -252.01%N/A -54.43% Does the media prefer TAK or INSM? In the previous week, Insmed had 4 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 6 mentions for Insmed and 2 mentions for Takeda Pharmaceutical. Takeda Pharmaceutical's average media sentiment score of 1.59 beat Insmed's score of 0.92 indicating that Takeda Pharmaceutical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Takeda Pharmaceutical 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Insmed 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community prefer TAK or INSM? Insmed received 442 more outperform votes than Takeda Pharmaceutical when rated by MarketBeat users. Likewise, 66.26% of users gave Insmed an outperform vote while only 56.82% of users gave Takeda Pharmaceutical an outperform vote. CompanyUnderperformOutperformTakeda PharmaceuticalOutperform Votes10056.82% Underperform Votes7643.18% InsmedOutperform Votes54266.26% Underperform Votes27633.74% Which has more volatility and risk, TAK or INSM? Takeda Pharmaceutical has a beta of 0.51, meaning that its stock price is 49% less volatile than the S&P 500. Comparatively, Insmed has a beta of 1.1, meaning that its stock price is 10% more volatile than the S&P 500. SummaryTakeda Pharmaceutical and Insmed tied by winning 9 of the 18 factors compared between the two stocks. Ad StocksToTradeliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the liberals broke”... But it turns out that was all just a smokescreen to hide the TRUTH…Click here to discover the real reason Elon Musk became buddy-buddy with Trump. Get Insmed News Delivered to You Automatically Sign up to receive the latest news and ratings for INSM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INSM vs. The Competition Export to ExcelMetricInsmedPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$12.62B$6.70B$5.23B$9.28BDividend YieldN/A2.98%5.12%4.28%P/E Ratio-12.7110.5587.6917.27Price / Sales36.79199.001,168.45119.91Price / CashN/A57.1543.2337.82Price / Book-30.405.174.834.94Net Income-$749.57M$151.96M$120.76M$225.76M7 Day Performance1.61%3.11%2.49%3.92%1 Month Performance-6.80%-4.17%17.55%1.71%1 Year Performance127.37%7.50%28.51%15.79% Insmed Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INSMInsmed3.0473 of 5 stars$70.53-0.1%$83.67+18.6%+134.8%$12.62B$342.96M-12.71373TAKTakeda Pharmaceutical4.4347 of 5 stars$13.07-0.2%N/A-6.3%$41.59B$4.55T22.5349,281Positive NewsALNYAlnylam Pharmaceuticals4.4421 of 5 stars$238.69-2.8%$298.09+24.9%+27.3%$30.79B$2.09B-91.102,100TEVATeva Pharmaceutical Industries1.9022 of 5 stars$22.06-0.1%$20.88-5.4%+113.9%$24.99B$16.77B-25.9537,851Options VolumeBGNEBeiGene2.4455 of 5 stars$177.24+0.4%$253.69+43.1%+3.1%$17.28B$3.32B-21.5110,600Positive NewsUTHRUnited Therapeutics4.6905 of 5 stars$363.24+1.0%$370.86+2.1%+64.8%$16.22B$2.76B15.951,168Positive NewsRPRXRoyalty Pharma4.6975 of 5 stars$25.21+1.2%$41.67+65.3%-8.4%$14.85B$2.27B13.0680Analyst UpgradePositive NewsVTRSViatris2.789 of 5 stars$12.44-0.6%$13.67+9.9%+16.4%$14.85B$15.05B-16.8138,000News CoverageGap DownGMABGenmab A/S4.2331 of 5 stars$20.59+1.4%$45.20+119.5%-34.9%$13.63B$19.84B19.992,204Positive NewsSMMTSummit Therapeutics3.3375 of 5 stars$18.31+2.5%$33.33+82.0%+701.7%$13.50B$700,000.00-65.39105RDYDr. Reddy's Laboratories1.0307 of 5 stars$15.40+0.2%$17.00+10.4%+16.4%$12.85B$299.87B24.6027,048 Related Companies and Tools Related Companies Takeda Pharmaceutical Competitors Alnylam Pharmaceuticals Competitors Teva Pharmaceutical Industries Competitors BeiGene Competitors United Therapeutics Competitors Royalty Pharma Competitors Viatris Competitors Genmab A/S Competitors Summit Therapeutics Competitors Dr. Reddy's Laboratories Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:INSM) was last updated on 12/26/2024 by MarketBeat.com Staff From Our Partners Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredElon Musk could help pay for your retirementElon Musk is the richest man in the world... And he's pouring trillions into a unique investment.Brownstone Research | SponsoredTSLA *BANG* incoming (bullet in the chamber rn)I just pinpointed 5 dirt-cheap stocks that could soar the second the shot goes off. Thanks to Donald Trump’...StocksToTrade | SponsoredWhy Buffett, Griffin and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Insmed Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Insmed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
